Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity

Formiga, Francisco Fellipe Claudino; Silva, Clóvis A.; Pedrosa, Tatiana do Nascimento; Aikawa, Nádia E.; Pasoto, Sandra Gofinet; Garcia, Cristiana C.; Capão, Artur; Martins, Victor Adriano de Oliveira; Proença, Adriana Coracini Tonacio de; Fuller, Ricardo; Yuki, Emily Figueiredo Neves; Vendramini, Margarete Borges Galhardo; Rosário, D.C.; Brandão, L.M.K.R.; Sartori, Ana Marli Christovam; Antonângelo, Leila; Bonfá, Eloísa; Borba, Eduardo Ferreira

doi:10.1177/09612033211040371

Cited by 4 publications

(1 citation statement)

References 33 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety, immunogenicity, and clinical efficacy of earlier standard dose influenza vaccination is well established in SLE patients [31–37]. Immunogenicity is lower in SLE patients with the standard vaccination, but additional booster vaccination does not improve immunogenicity [32,37].…”

Section: Special Implications Of Influenza Vaccination In Systemic Lu...mentioning

confidence: 99%

Vaccination updates and special considerations for systemic lupus erythematosus patients

Law,

Sorrento,

Saxena

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review We review the latest guidelines and note special considerations for systemic lupus erythematosus (SLE) patients when approaching vaccination against SARS-CoV-2, influenza, pneumococcus, herpes zoster, and potentially respiratory syncytial virus (RSV) vaccine in the future. Recent findings SLE patients have unique infectious risks due to newer treatments and the nature of the disease itself. It is important to balance the benefit of additional protective immunity from updated vaccines against the possible risk of disease activity exacerbations. Summary It is important to continuously evaluate the safety and immunogenicity of updated vaccines specifically for SLE patients. Additionally, the newly approved RSV vaccine should be considered for this population to reduce severe respiratory illness.

show abstract

Section: Special Implications Of Influenza Vaccination In Systemic Lu...mentioning

confidence: 99%

Vaccination updates and special considerations for systemic lupus erythematosus patients

Law,

Sorrento,

Saxena

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Robust immunogenicity to the H3N2 component of influenza A vaccine in primary Sjögren syndrome

Pasoto¹,

Borba²,

Formiga³

et al. 2023

Clin Rheumatol

View full text Add to dashboard Cite

Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies

Li,

Huang

et al. 2024

Annals of Medicine

View full text Add to dashboard Cite

Background Systemic lupus erythematosus (SLE), an extensive autoimmune disorder, compromises viral resistance and alters immune responses post respiratory virus vaccines. This study aims to assess immune response levels and safety in SLE patients following respiratory virus vaccines. Methods Extensive searches, until 1 March 2024, were conducted using PubMed, EMBASE, and Cochrane Library. Outcomes, encompassing seroconversion rate (SCR), antibody and IgG titers, neutralizing antibodies, anti-spike antibodies, anti-receptor binding domain (RBD) IgG, and adverse events, were appraised. Results Sixteen articles, comprising 25 observational studies, were included. SLE patients exhibited lower SCR (OR = 0.42, 95%CI: 0.26 to 0.69), antibody titers (SMD=-2.84, 95%CI: −3.36 to −1.61), and neutralizing antibodies (OR = 0.27, 95%CI: 0.13 to 0.56) compared to the healthy population post respiratory virus vaccines. Notably, differences were statistically insignificant for anti-RBD IgG (OR = 1.75, 95%CI: 0.10 to 29.42), IgG titers (SMD=-2.54, 95%CI: −5.57 to −0.49), anti-spike antibodies (OR = 0.35, 95%CI: 0.08 to 1.53), injection site discomfort (OR = 1.03, 95%CI: 0.52 to 2.06), fatigue (OR = 1.23, 95%CI: 0.74 to 2.03), fever (OR = 1.02, 95%CI: 0.64 to 1.63), localized reactions (OR = 0.69, 95%CI: 0.37 to 1.30), systemic reactions (OR = 1.00, 95%CI: 0.59 to 1.69), allergic reactions (OR = 5.11, 95%CI: 0.24 to 107.10), self-reported vaccination-related adverse events (OR = 1.61, 95%CI: 0.56 to 4.63), and disease flares after vaccination (OR = 1.00, 95%CI: 0.14 to 7.28). Conclusion Despite the reduced immune response and host protection in SLE patients post-Corona Virus Disease 2019 (COVID-19) and influenza vaccines compared to the healthy population, safety profiles are comparable. Therefore, it is recommended that SLE patients receive COVID-19 and influenza viral vaccines to fortify their resistance.

show abstract

Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity

Cited by 4 publications

References 33 publications

Vaccination updates and special considerations for systemic lupus erythematosus patients

Vaccination updates and special considerations for systemic lupus erythematosus patients

Robust immunogenicity to the H3N2 component of influenza A vaccine in primary Sjögren syndrome

Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies

Contact Info

Product

Resources

About